1. Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Treatment Algorithm

5. Testing for Targetable Mutations and Biomarkers

6. Upfront Testing

7. Treatment Algorithm Focus on Absence of Targetable Mutations

8. Case 1 Newly Diagnosed

9. Treatment Approach for Case 1 Patient

10. Clinical Data Support Combination Therapy Over Chemotherapy

11. Discussion on When to Use Combination Therapy

12. Clinical Data Support Combination Therapy Over Chemotherapy (cont)

13. Discussion on When to Use Chemotherapy Alone Over Combination Therapy

14. Chemotherapy Options

15. Shared Decision Making

16. Importance of Patient Communication on QoL and Outcomes: Study Design

17. Data on the Importance of Patient Communication on QoL and Outcomes

18. Strategies to Effectively Incorporate Patient Communication Into Practice

19. Role of Oncology Nurses in Patient Management

20. Patient Resources

21. Case 2 Second-Line

22. Treatment Approach for Patient 2

23. Immunotherapy as a Third-Line Option for Case 2

24. When Might Immunotherapy Not Be Worth the Risk?

25. Factors That Guide Choice of Immunotherapy

26. Considerations for Treatment Selection

27. Abbreviations

28. Abbreviations (cont)